CYBN

Cybin, Inc. · AMEX

Sector Health Technology
Industry Pharmaceuticals: Major
Website cybin.com
Employees(FY) 50
ISIN CA23256X4075

Performance

-4.62%

-2.19%

+10.82%

-16.09%

-28.37%

YTD

-34.95%

Profile

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

Advanced Technical Analysis

Technical Analysis of CYBN 2024-11-20

The stock exhibits a bullish sentiment overall, with a strong Moving Average Score of 76 indicating positive momentum, while the Oscillators Score of 46 suggests a neutral stance, and the Technical Score of 61 reinforces the bullish outlook. This combination implies a generally favorable market condition, though caution may be warranted due to t...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CYBN

Stock Rank

Recent News & Updates

2024-11-17 18:00
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder(Yahoo Finance)
2024-11-13 18:30
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024(Yahoo Finance)
2024-11-12 18:30
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results(Yahoo Finance)
2024-10-30 19:30
Cybin to Participate at the 2024 Milken Institute Future of Health Summit(Yahoo Finance)
2024-10-23 19:30
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program(Yahoo Finance)
2024-10-02 19:30
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024(Yahoo Finance)
2024-09-30 19:30
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program(Yahoo Finance)
2024-09-23 19:30
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit(Yahoo Finance)
2024-09-19 17:38
Cybin Provides Corporate Update on Upcoming Clinical Milestones(Business Wire)
2024-09-18 19:26
Cybin Announces Completion of Previously Announced Share Consolidation(Yahoo Finance)
2024-09-03 19:55
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference(Yahoo Finance)
2024-08-27 07:01
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation(Yahoo Finance)
2024-08-12 19:30
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder(Yahoo Finance)
2024-08-07 19:36
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights(Yahoo Finance)
2024-08-06 19:30
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference(Yahoo Finance)
2024-07-07 20:38
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update(Yahoo Finance)
2024-06-27 00:00
What Makes Cybin Inc. (CYBN) a New Buy Stock(Yahoo Finance)
2024-06-25 19:41
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights(Yahoo Finance)
2024-06-18 19:30
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference(Yahoo Finance)
2024-06-10 21:35
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround(Yahoo Finance)
2024-06-10 19:30
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development(Yahoo Finance)
2024-05-28 19:30
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024(Yahoo Finance)
2024-05-13 19:30
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase(Yahoo Finance)
2024-05-05 20:32
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones(Yahoo Finance)
2024-04-24 19:30
Cybin to Participate at the 27th Annual Milken Institute Global Conference(Yahoo Finance)
2024-04-17 19:30
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry(Yahoo Finance)
2024-04-15 19:30
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder(Yahoo Finance)
2024-04-09 19:30
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference(Yahoo Finance)
2024-03-18 23:53
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million(Yahoo Finance)
2024-03-17 19:30
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas(Yahoo Finance)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.